EnsoData uses Artificial Intelligence (AI) to unlock more rapid, accurate, and affordable diagnoses of the biggest threats to human health.
Over the past eight years, EnsoData has pioneered the clinical use and adoption of artificial intelligence (AI) and machine learning (ML) technology in sleep medicine (and healthcare more broadly) to solve large-scale problems at the heart of diagnosis and treatment decision-making.
EnsoData’s primary solution, EnsoSleep, was cleared by the FDA in 2017 to provide diagnostic analysis of in-lab sleep studies. EnsoSleep received expanded FDA clearance in 2021 to score and analyze home sleep studies, to add a viewing, editing, and reporting platform, and to record and output a total sleep time measurement.
The latest EnsoData AI algorithm, EnsoSleep PPG, was cleared by the FDA in February of 2024. EnsoSleep PPG turns the widely available and wearable FDA-cleared pulse oximetry technology into a diagnostic tool for clinicians.
This new clearance offers opportunities for clinicians to effectively reach patients by enabling AI-driven analysis using more accessible and cost-effective pulse oximeters.
Ultimately, our suite of AI tools help clinicians reduce healthcare turnaround times, cut into patient backlogs, and ultimately, improve the patient care journey and health outcomes.
-
所属行业
-
医院和医疗保健
-
规模
-
51-200 人
-
总部
-
Madison，Wisconsin
-
类型
-
私人持股
-
创立
-
2015
-
领域
-
Machine Learning、Big Data、Cloud Computing、Signal Processing、Artificial Intelligence、AI、sleep medicine和sleep
